GC-MS with Ethyl Chloroformate Derivatization for Comprehensive Analysis of Metabolites in Serum and its Application to Human Uremia by Jia, Wei & NC DOCKS at The University of North Carolina at Greensboro
GC-MS with Ethyl Chloroformate Derivatization for Comprehensive Analysis of 
Metabolites in Serum and its Application to Human Uremia  
 
By: Xiumei Tao, Yumin Liu, Yihuang Wang, Yunping Qiu, Jingchao Lin, Aihua Zhao, 
Mingming Su, and Wei Jia 
 
Tao, X., Liu, Y., Qiu, Y., Lin, J., Zhao, A., Su, M., & Jia, W. (2008). GC-MS with ethyl 
chloroformate derivatization for comprehensive analysis of metabolites in serum and its 
application to human uremia. Analytical and Bioanalytical Chemistry, 391, 2881-288. 
 
 
***Note: This version of the document is not the copy of record. Made available courtesy of 
Springer Verlag. The original publication is available at www.springerlink.com. 
Link to Article: http://www.springerlink.com/content/q1373632t160530n/ 
 
 
 
 
Abstract: 
An optimized method based on GC-MS with ethyl chloroformate derivatization has been 
developed for the comprehensive analysis of endogenous metabolites in serum. Twenty-two 
reference standards and serum samples were used to validate the proposed method. The 
correlation coefficient was higher than 0.9900 for each of the standards, and the LOD varied 
from 125 to 300 pg on-column. The analytical equipment exhibited good repeatability 
(RSD<10%) for all of the standards. Both the repeatability and the within-48-h stability of the 
analytical method were satisfactory (RSD<10%) for the 18 metabolites identified in the serum 
samples. Mean recovery was acceptable for the 18 metabolites, ranging from 70% to 120% with 
RSDs of less than 10%. Using the optimized protocol and a subsequent multivariate statistical 
technique, complete differentiation was achieved between the metabolic profile of uremic 
patients and that of age- and sex-matched normal subjects. Significantly decreased levels of 
valine, leucine, and isoleucine and increased levels of myristic acid and linoleic acid were 
observed in the patient group. This work demonstrated that this method is suitable for serum-
based metabolic profiling studies.  
 
Article: 
INTRODUCTION 
Following the completion of the Human Genomic Project, tremendous advances in high-
throughput “-omics” sciences such as genomics, proteomics, and metabonomics (also called 
metabolomics and metabolic profiling) have been made in recent years [1–3]. Metabonomics is a 
newly developed technology for the quantitative measurement of dynamic multiparametric 
metabolic changes of living systems exposed to pathophysiological stimuli or genetic 
modifications [4]. The footstone of metabonomics is to reliably measure as many metabolites as 
possible in biological samples, including body fluids (e.g., urine, serum, amniotic fluid, 
cerebrospinal fluid), single cells and tissues of given organisms or plants, using modern high-
throughput analytical instruments. The main analytical techniques usually involve nuclear 
magnetic resonance (NMR) [5–8], liquid chromatography–mass spectrometry (LC-MS and LC-
MS-MS) [9–11], capillary electrophoresis–mass spectrometry (CE-MS) [12, 13], and gas 
chromatography–mass spectrometry (GC-MS) [14, 15]. GC-MS has long been used for 
metabolic profiling study due to its high sensitivity, reliability and the ease of metabolite 
identification. As most endogenous metabolites exhibit little or no volatility in biological 
samples, suitable sample preparation—and derivatization in particular—is the prerequisite for a 
GC-MS assay. Trimethylsilyl (TMS) derivatization agents, such as bis(trimethylsilyl) 
trifluoroacetamide (BSTFA) and N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) 
containing 1% trimethylchlorosilane (TMCS), have been frequently applied in GC-MS-based 
metabolic profiling studies [16, 17]; however, TMS derivatization only proceeds in nonaqueous 
media, and the entire reaction procedure is very labor-intensive and time-consuming [15]. As an 
effective alternative to TMS, ethyl chloroformate (ECF) is a suitable derivative agent for a broad 
array of low molecular weight metabolites (generally, MW <1000 Da) including organic acids, 
amines, amino acids, and aminoalcohols that are present in biological matrices [18–20]. 
Recently, we successfully applied an optimized two-step ECF derivatization protocol to GC-MS-
based urinary metabonomic studies. Compared to previous work [19], the currently proposed 
two-step ECF derivatization for GC-MS analysis exhibited better derivatization efficiency and 
provided more useful information [15], a crucial aspect in metabonomic studies. However, this 
approach has not yet been assessed when used for metabonomic studies of serum samples.  
 
Uremia is a clinical syndrome characterized by abnormal accumulations of certain compounds, 
which are normally secreted into the urine by the kidneys in healthy subjects [21]. If these 
retained compounds interfere with physiological functions, they can result in different levels of 
renal toxicity. Moreover, uremia commonly develops with many complications, such as 
hypertension, dyslipidemia, diabetes, etc. [22], each of which results in devastating effects on 
patients. Due to a lack of sufficient donor kidneys, the current treatment for uremia is usually 
still dialysis. Thus, a comprehensive understanding of uremic solutes and their toxic effects will 
make dialysis more safe and rational. However, due to the analytical challenges presented by 
complex biological matrices and the extreme variability of this syndrome, the study of significant 
alterations of certain endogenous metabolites closely associated with human uremia remains 
incomplete.  
 
In this study, we describe an optimized ECF derivatization procedure for the comprehensive 
analysis of serum samples using GC-MS. The developed method was extensively validated using 
a large set of standards with varied chemical properties as well as complex serum samples. 
Furthermore, the optimized method was employed to profile and characterize the significantly 
altered metabolites in uremic human serum. This study will extend our previously optimized 
two-step ECF derivatization for the global analysis of urine samples using GC-MS, and provide 
a complementary measure for identifying metabolites associated with human pathology, leading 
comprehensive understanding and effective treatments of complex human diseases.  
 
EXPERIMENTAL 
Materials and methods 
Ethyl chloroformate (ECF), pyridine, anhydrous ethanol, sodium hydroxide, chloroform, n-
hexane, and anhydrous sodium sulfate of analytical grade were from the China National 
Pharmaceutical Group Corporation (Shanghai, China). L-2-chlorophenylalanine (Shanghai 
Intechem Tech. Co. Ltd., China) was used as an internal standard for batch quality control. All of 
the standards (Table 1), which were commercially obtained from Sigma-Aldrich (St. Louis, MO, 
USA), were prepared in ultrapure water (Milli-Q system, Millipore, Billerica, MA, USA) or 
ethanol solution (Sigma-Aldrich). Blood samples of 24 uremic patients and 23 age- and sex-
matched healthy controls were collected from Shanghai Dongfang hospital (Shanghai, China). 
The clinical study was approved by the local ethics committee and all of the volunteers gave 
their written, informed consent. Serum was prepared by centrifugation at 1,400×g for 5 min at 
4 °C, and stored at −80 °C prior to the GC-MS assay.  
 
 
Table 1: Linearities, LODs and repeatabilities of the test compounds  
Compound Linear (μg/ml)a  n  R 2, b  LOD Repeatability (%)e  
pg on columnc  S/N ratiod  RSD 
Amino acids              
Alanine 0.1–12.5 9 0.9990 125 16 3.9 
Asparagine 0.5–12.5 7 0.9921 200 27 7.7 
Aspartic acid 0.1–12.5 8 0.9946 150 22 4.1 
Cysteine 0.25–12.5 8 0.9919 200 26 4.5 
Glycine 1–12.5 6 0.9944 300 38 8.9 
Isoleucine 0.1–12.5 9 0.9951 125 15 3.1 
Leucine 0.1–12.5 9 0.9938 125 10 4.2 
Methionine 0.1–12.5 8 0.9931 150 27 4.5 
Phenylalanine 0.1–12.5 9 0.9967 125 12 4.8 
Proline 1–12.5 7 0.9987 125 31 9.2 
Threonine 0.1–12.5 9 0.9953 250 33 4.9 
Tyrosine 0.1–12.5 9 0.9909 125 22 4.5 
Valine 0.1–12.5 9 0.9990 125 18 4.0 
Amine              
Tyramine 0.5–12.5 7 0.9935 200 36 4.3 
Organic acids              
Butanedioic acid 0.1–12.5 9 0.9991 125 26 3.1 
Citrate 1–12.5 6 0.9912 300 35 4.7 
Hexadecanoic acid 0.1–12.5 9 0.9931 250 18 3.9 
Malic acid 0.5–12.5 7 0.9960 125 31 2.1 
Octadecanoic acid 0.1–12.5 9 0.9902 300 33 4.2 
9,12-Octadecadienoic acid 0.5–12.5 7 0.9908 150 37 8.2 
Propanoic acid 0.1–12.5 9 0.9982 125 19 2.9 
Tetradecanoic acid 0.1–12.5 9 0.9967 150 19 4.1 
aStock solutions of test compounds were prepared in distilled water or ethanol at 1 mg/ml and stored at −4 °C. The mixed standard solution was 
obtained through the addition of a 100-μl aliquot of stock solution in order to obtain a concentration of 100 μg/ml. The linear range for each 
compound was determined by diluting the mixed standard solution at different concentrations.  
bThe correlation coefficient (r-square) was calculated for the concentration range shown.  
cLOD (limit of detection, pg on column) was obtained by calibrating the injection of the standard solution with a S/N ratio ≥3.0.  
dS/N ratios were claculated in order to show the peak-to-peak values by TurboMass software.  
eThe repeatability was evaluated by RSD for the 22 test compounds at concentrations of 1 μg/ml for amino acids and organic acids and 5 μg/ml 
for the amine using six identical samples; the aim was to evaluate the repeatability of the analytical equipment.  
 
ECF derivatization 
Each 600-μl aliquot of the diluted serum sample (serum: water = 1:1, v/v) or the mixture of the 
22 test standards was added to a glass tube with a screw top and combined with 100 μl of L-2-
chlorophenylalanine (0.1 mg/ml), 400 μl of anhydrous ethanol, 100 μl of pyridine and 50 μl of 
ECF for the first step of the derivatization reaction. The resulting mixture was ultrasonicated at 
20.0 °C and 40 kHz for 60 s to accelerate the reaction, and subsequently extracted with 500 μl of 
n-hexane. After the pH of the aqueous layer had been carefully adjusted to 9–10 using 100 μl of 
NaOH (7 mol/l), the second step of the ECF derivatization procedure was carried out by 
supplying an additional 50 μl of ECF to the system. The products arising from the two 
consecutive derivatization steps were vortexed for 30 s and centrifuged for 5 min at 1,400×g. 
After carefully transferring 300 μl of the supernatant to a screw-topped glass vial, an additional 
500 μl of n-hexane was added to the residue in order to extract the derivatives. A total of 400 μl 
of the supernatant was transferred to a screw-topped glass vial, and a combined 700 μl of n-
hexane extracts were dried with a gentle stream of nitrogen at room temperature. The resulting 
residue was resolved in 200 μl of chloroform, and a small amount of anhydrous granular sodium 
sulfate was added to remove any traces of water for the subsequent GC-MS assay.  
 
GC-MS assay 
Each 1-μl aliquot of the analyte was injected in a splitless mode into a PerkinElmer gas 
chromatography system coupled to a TurboMass-Autosystem XL mass spectrometer 
(PerkinElmer, Waltham, MA, USA). A DB-5MS capillary column coated with 5% diphenyl 
crosslinked with 95% dimethylpolysiloxane (30 m × 250 μm i.d., 0.25-μm film thickness; 
Agilent J & W Scientific, Folsom, CA, USA) was used to separate the ECF derivatives. The 
initial temperature of the oven temperature was held at 80 °C for 2 min, ramped to 140 °C at a 
rate of 10 °C/min, to 240 °C at a rate of 4 °C /min, to 280 °C at a rate of 10 °C/min, and then 
held at 280 °C for 3 min. Helium was used as carrier gas at a constant flow rate of 1 ml/min 
through the column. The temperatures of the ion source and injector were 200 °C and 260 °C, 
respectively. The electron energy was 70 eV and mass data were collected in a full scan mode 
(m/z 30–550). The dwell time for each scan was set at 100 ms and the solvent delay at 3 min.  
 
Analytical method validation 
The linear concentration range and the correlation coefficient (r 2) were obtained for each test 
standard by using a series of standard solutions at different concentrations. Injections were 
performed in triplicate for each concentration and the average value was used to establish the 
calibration curves. Typically, the r 2 value should be greater than 0.9900 within the linear 
concentration range. The limit of detection (LOD) was determined for each test standard by 
analyzing the signal-to-noise ratio (S/N) provided by the TurboMass interface. The LOD was 
defined as a S/N value of ≥3.0 in this study.  
 
The repeatability of the analytical method was evaluated using six independently prepared 
samples, and the repeatability of the analytical instrument was found by repeatedly measuring 
the same sample six times. Sample stability was assessed by measuring the peak areas of the 
compound identifiable from the serum at different time points: 0 h, 6 h, 12 h, 24 h, 48 h, 60 h, 
and 72 h.  
 
The recovery was evaluated by adding 18 representative compounds, including organic acids, 
amino acids and an amine, at three different concentrations of 1 μg/ml, 2.5 μg/ml, and 5 μg/ml to 
serum samples. In the method validation experiments, the peak area for each test compound was 
integrated by TurboMass software (v. 4.0, PerkinElmer) and adjusted using the peak area of the 
internal standard.  
 
Data analysis 
Unprocessed GC-MS data files generated by the metabolic profiling of serum samples from 24 
uremic patients and 23 normal subjects were converted into NetCDF format via DataBridge 
(Perkin-Elmer) and processed by custom scripts in MATLAB R2007a (The MathWorks, Natick, 
MA, USA), during which noise elimination, peak identification and alignment, and exclusion of 
the internal standard and impurities were automatically performed [23]. The resulting three-
dimensional matrix consisting of peak indices (retention time (RT)-m/z pairs), sample names 
(observations), and normalized peak areas (variables) was introduced into the SIMCA-P 11.0 
software package (Umetrics, Umeå, Sweden) in order to perform multivariate statistical analyses 
including principal component analysis (PCA) and orthogonal partial least squares projection to 
latent structures discriminant analysis (OPLS-DA).  
 
PCA, an unsupervised pattern recognition method, is commonly used to detect the possible 
outliers and natural clusters among observations [23–25]. In this study, PCA was conducted on 
mean-centered, pareto-scaled spectral data from the serum samples. The mean-centering 
procedure subtracts the average spectrum of the datasets, and the pareto-scaling method weighs 
each variable according to the square root of its standard deviation. One of the main reasons for 
using the pareto-scaling method is that such procedure is a satisfactory comprise between UV-
scaling (scaling to unit variance), which gives equal weight to the baseline noise and individual 
signals in the entire chromatogram, and no scaling, which could fail to pick out small changes in 
metabolites with lower concentrations [23]. Additionally, in order to maximize the 
discrimination of metabolic profiles of uremic patients from those of the healthy controls, an 
OPLS-DA model—a supervised method capable of removing information unrelated to the 
response matrix Y (commonly set to 0/1, etc.) from an original matrix X—was utilized 
accordingly. Variable importance in the projection (VIP) values were obtained for the variables 
in the OPLS-DA model in order to select the differentially expressed metabolites, and variables 
with VIP values greater than 1.0 were considered statistically significant metabolites. In parallel, 
the regression coefficients from the OPLS-DA model were used to look for the up- or 
downregulations of these significant metabolites in the uremic patient group compared to the 
control subject group.  
 
Default seven-round crossvalidation was performed using the SIMCA-P software by excluding 
one-seventh of all the samples from the model in each round in order to validate the model 
against overfitting. This procedure was repeated in an iterative manner until each sample had 
been excluded once. The cumulative value of R2Y (R2Ycum) provides an estimate of how well 
the model fits the Y data, and the cumulative value of Q2Y (Q2Ycum) is an estimate of how well 
the model predicts the Y data. When R2Ycum and Q2Ycum approach 1.0, it indicates that a 
robust model with a reliable predictability has been obtained. In order to check the results from 
the multivariate statistical analyses, a univariate statistical analysis of the t-test experiments was 
subsequently performed. Based on the fold-change rank and p-values from the t-tests, the 
differentially expressed metabolites identified from the multivariate statistical analyses were 
validated at the univariate analysis level. The critical p-value for statistical significance in the t-
tests was set to 0.05 in this study.  
 
RESULTS AND DISCUSSION 
Derivatization procedure 
The derivatization procedure is an indispensable step in the GC-MS analysis of compounds with 
little or no volatility. In contrast to TMS derivatization, ECF derivatization proceeds in aqueous 
media and does not necessarily involve the removal of water before and during the reaction, 
which facilitates large-scale sample preparation and greatly improves batch reproducibility [15]. 
Secondly, the extraction efficiencies of chloroform and n-hexane are comparable, but n-hexane 
was used to extract the derivatives in this study. The major reason for this is that the presence of 
n-hexane in the upper layer of the resulting mixture facilitates solvent removal from the vial. 
Thirdly, the dried derivatives were resolvated in 200 μl of chloroform for the GC-MS assay 
because chloroform has a lower volatility than n-hexane and exhibits a better separation in the 
GC-MS chromatogram for the test samples used in this study. Lastly, it was necessary to adjust 
the pH to 9–10 with 7 mol/l NaOH during the derivatization process so that groups such as –
COOH, –NH2 and –OH could be easily targeted by ECF. Using such a procedure, the 22 mixed 
standards were clearly separated in the GC-MS total ion current (TIC) chromatogram (Fig. 1), 
and a total of 18 compounds, including an array of amino acids, organic acids, and an amine, 
were consistently detected in serum samples using GC-MS spectral library databases of the 
reference standards available.  
 
 
Figure 1: The GC-MS total ion current (TIC) chromatogram of the 22 test compounds. 1, Propanoic acid; 2, 
butanedioic acid; 3, alanine; 4, glycine; 5, valine; 6, leucine; 7, isoleucine; 8, proline; 9, threonine; 10, malic acid; 
11, asparagine; 12, aspartic acid; 13, citrate; 14, methionine; 15, tetradecanoic acid; 16, phenylalanine; 17, cysteine; 
18, hexadecanoic acid; 19, tyramine; 20, 9,12-octadecadienoic acid; 21, octadecanoic acid; 22, tyrosine  
 
Analytical method validation 
Linearity and LOD. The calibration curve for each test standard was obtained using at least six 
different concentrations (Table 1). The corresponding concentration range varied from 0.1 to 
12.5 μg/ml for most amino acids and organic acids, and from 0.5 to 12.5 μg/ml for amine, with 
r 2 approaching 1.0000. Exceptions were compounds such as glycine, proline, aspagine, cysteine, 
malic acid, citrate and 9,12-octadecadienoic acid, which exhibited better linearity at high 
concentrations, and thus r 2 was calculated for these compounds by excluding lower 
concentrations. The S/N values for most of the test standards were larger than 3.0 (Table 1), 
allowing the LOD to be individually calculated each compound.  
 
Repeatability, stability and recovery. The analytical equipment exhibited satisfactory 
repeatabilities for the 22 test compounds, with RSDs of better than 10% (Table 1). The analytical 
method gave good repeatability for the 18 test compounds identified in serum samples, with 
RSDs of less than 10% (Table 2). Similar results were obtained by three different operators in 
our laboratory.  
 
Table 2: Repeatabilities, stabilities and recoveries of the test compounds  
Compound Repeatability (%) a  Stability (48h, %)b  Recovery (%)c  
RSD R.S.D Average RSD 
Amino acids          
Alanine 3.2 5.9 114.2 7.1 
Aspartic acid 4.3 6.2 98.3 4.3 
Cysteine 4.9 8.3 81.4 8.6 
Glycine 9.9 8.0 70.1 9.2 
Isoleucine 3.8 3.9 86.3 8.1 
Leucine 4.6 4.1 101.9 4.3 
Methionine 4.7 7.6 82.2 5.5 
Phenylalanine 6.9 7.1 76.7 6.8 
Proline 9.3 9.2 70.5 9.1 
Threonine 3.9 5.2 101.3 8.3 
Valine 4.7 3.4 98.1 6.5 
Organic acids          
Butanedioic acid 4.2 3.9 72.3 9.5 
Hexadecanoic acid 4.6 7.9 82.5 5.2 
Octadecanoic acid 4.9 9.7 116.3 8.7 
9,12-Octadecadienoic acid 5.9 9.8 81.2 5.9 
Propanoic acid 3.7 4.8 71.2 4.0 
Tetradecanoic acid 4.5 8.6 106.4 2.8 
Amine          
Tyramine 4.7 9.0 71.9 8.3 
aRepeatability was determined using six different samples for the 18 test compounds (at concentrations of 1 μg/ml for amino acids and organic 
acids and 5 μg/ ml for the amine); the aim was to evaluate the repeatability of the analytical method.  
bStability over 48 h was measured for the 18 compounds at concentrations of 1 μg/ml for amino acids and organic acids and 5 μg/ ml for the 
amine.  
cMean recovery was obtained for the 18 test compounds (using three replicate samples at three different concentrations).  
 
In addition, the stabilities of most of the 18 test compounds in the serum were fairly acceptable, 
with RSDs of less than 10% within 48 h (Table 2). It is worth noting that the RSDs of certain 
compounds such as asparagine and 9,12-octadecadienoic acid were greater than 15% after 60 h. 
Moreover, the overall sensitivity appeared to decrease when the GC-MS was used normally over 
48 h. Therefore, all of the samples from each batch were analyzed within 48 h, and maintenance 
of the equipment was carried out after every 48-h analysis.  
 
The mean recoveries of the 18 test compounds ranged from 70 to 120%, with RSDs of less than 
10% (Table 2), which is acceptable for the global analysis of endogenous metabolites in serum 
samples.  
 
In summary, the proposed method offered a reliable and stable measurement approach for a wide 
array of metabolites with diverse chemical characteristics, which aided the global analysis of 
metabolites in serum samples from certain pathophysiological states.  
 
Clinical application. There is an urgent need for the comprehensive analysis of uremic solutes 
with varied physiochemical characteristics before the extensive application of therapeutic 
strategies such as dialysis and kidney transplantation. To this end, we applied a global metabolic 
profiling technology to unbiasedly identify the crucial metabolites closely associated with human 
uremia. The approach used employed a combination of a GC-MS assay with modern multivariate 
statistical techniques. Fifty compounds (about 56%) out of the 90 peaks detected in the serum 
samples were identified by comparing their mass fragmentation with those from GC-MS spectral 
databases, including those of NIST and Wiley, using Turbomass 4.1.1 software (PerkinElmer). 
Eighteen of these compounds were verified by reference standards available in this work 
(Table 3).  
 
Table 3: List of compounds identified in the serum samples using GC-MS spectral library 
databases  
Key RT (min)b  m/z c  Compounds Revd  
1a  7.030 45, 74, 29, 56, 117 2-Hydroxypropanoic acid 890 
2a  7.197 101, 129, 73, 55, 147 Butanedioic acid 797 
3a  8.592 116, 72, 70, 44, 29 Alanine 955 
4a  8.863 102, 74, 57, 45, 29, 85 Glycine 793 
5a  10.448 144, 101, 116, 72, 55 Valine 786 
6a  11.784 158, 102, 43, 58, 72 Leucine 912 
7a  12.091 158, 102, 129, 69, 74 Isoleucine 921 
8a  12.461 142, 70, 98, 114, 41 Proline 905 
9a  12.870 145, 117, 102, 73, 45 Theronine 770 
10 14.446 88, 101, 73, 157, 228 Dodecanoic acid 851 
11a  15.902 188, 142, 116, 70, 56 Aspartic acid 628 
12 16.021 203, 157, 115, 87, 43 1,2,3-Propanetricarboxylic acid 939 
13a  17.618 61, 114, 129, 175, 74 Methionine 913 
14 18.724 202, 156, 128, 84, 56 Glutamic acid 856 
15a  19.052 88, 101, 158, 256, 211 Tetradecanoic acid 917 
16 19.672 57, 68, 82, 222, 240 Hexadecanal 961 
17a  20.306 91, 176, 192, 220, 265 Phenylalanine 866 
18a  21.309 74, 102, 220, 132, 174 Cysteine 480 
19 21.408 88, 101, 157, 225, 270 Pentadecanoic acid 890 
20 21.675 43, 57, 97, 110, 208 Hexadecanenitrile 977 
21 23.111 88, 152, 194, 236, 282 9-Hexadecenoate 909 
22 23.231 88, 152, 194, 236, 282 11-Hexadecenoic acid 948 
23a  23.778 88, 101, 157, 241, 284 Hexadecanoic acid 971 
24 23.980 226, 210, 74, 125, 154 Fenclonine 672 
25 24.407 57, 68, 82, 222, 250 Octadecanal 971 
26 25.143 88, 101, 157, 255, 298 Heptadecanoic acid 824 
27a  27.146 55, 67, 81, 211, 280 9,12-Octadecadienoic acid 914 
28 27.511 67, 81, 220, 262, 308 Linoleate 928 
29 27.632 88, 180, 222, 264, 310 Oleate 960 
30 27.752 88, 180, 222, 264, 310 9-Octadecenoate 971 
31 27.954 79, 95, 108, 261, 306 9,12,15-Octadecatrienoic acid 731 
32 27.988 91, 131, 146, 192, 248 Benzyl-L-glutamate  665 
33a  28.210 88, 101, 157, 269, 312 Octadecanoic acid 907 
34 28.624 156, 56, 84, 102, 128 Lysine 609 
35 30.317 88, 101, 157, 283, 326 Nonadecanoic acid 779 
36 30.839 79, 91, 203, 217, 332 5,8,11,14-Eicosatetraenoic acid 956 
37 30.980 79, 91, 201, 215, 330 5,8,11,14,17-Icosapentaenoate acid 944 
38 31.282 79, 93, 135, 150, 334 11,14,17-Eicosatrienoic acid 861 
39 31.717 81, 95, 150, 291, 336 11,14-Eicosadienoic acid 904 
40 31.814 81, 95, 262, 292, 338 11-Eicosadienoic acid 884 
41 31.971 59, 72, 126, 264, 281 9-Octadecenamide 955 
42a  32.147 107, 135, 192, 264, 74 Tyrosine 749 
43 32.388 88, 101, 157, 297, 340 Eicosanoic acid 796 
44 32.605 59, 72, 128, 240, 281 Octadecanamide 924 
45 33.895 130, 117, 203, 101, 73 Tryptophan 589 
46 34.475 67, 79, 91, 262, 356 4,7,10,13,16,19-Docosahexaenoic acid 923 
47 37.543 81, 145, 247, 353, 368 Cholesta-3,5-diene 926 
48 38.894 81, 135, 247, 366, 351 Cholesta-4,6-dien-3-ol 933 
49 39.168 81, 147, 260, 353, 368 Cholest-5-en-3-ol(3β)-acetate 935 
50 42.896 81, 145, 275, 368, 386 26-Nor-5-cholesten-3β-ol-25-one 896 
aCompounds were verified using the reference compounds available; the remaining compounds were identified by the commercial compound 
libraries from NIST and Wiley in Turbomass 4.1.1 software (PerkinElmer).  
bRT, retention time  
cTypical ion fragmentations for the compound.  
dThe Rev values express the closeness of the matches of the spectra with NIST and Wiley library spectra; the ideal value for Rev is 999 in the 
Turbomass interface.  
 
Visual examination of the representative GC-MS total ion current (TIC) chromatograms showed 
obvious differences between uremic patients and healthy controls (Fig. 2), but the inherent 
complexity of the GC-MS chromatograms made direct comparison between groups impractical. 
Hence, multivariate statistical analyses, including PCA and OPLS-DA, were used to extract 
meaningful information from the complex biological samples. An initial 3D-PCA scores plot 
(Fig. 3) showed that there were no outliers among the subjects and that the subjects were 
naturally clustered into two broad classes. The resulting groupings were in good agreement with 
their clinical profiles and were verified by the clear separation in the PC1 of OPLS-DA model 
(Fig. 4), which was constructed from one predictive and two orthogonal components. The 
R2Ycum of 0.826 and the Q2Ycum of 0.771 demonstrated the high robustness of the OPLS-DA 
model. The p-values of the t-tests for all metabolites that gave VIP values of more than 1 in the 
OPLS-DA were less than 0.05 in this study. Based on the VIP values, the results of the t-tests 
and the GC-MS spectral libraries, we identified two fatty acids, myristic acid (tetradecanoic acid) 
and linoleic acid (9,12-octadecadienoic acid), and three significantly decreased amino acids, 
valine, leucine and isoleucine, that were present at significantly raised levels in the uremic 
patients as compared to the normal subjects. The changes in the levels of these compounds were 
considered metabolic responses to the uremic syndrome (Table 4).  
 
 
 
 
Figure 2: GC-MS TIC chromatograms of typical serum samples from different groups (the control subjects group 
and the uremic patients group)  
 
 
Figure 3: 3D-PCA scores plot for the GC-MS analysis of serum samples from uremic patients and normal subjects. 
Each symbol represents an individual subject (triangles, the control group; diamonds, the uremic group)  
 
 
 
 
 
 
Figure 4: OPLS-DA for the GC-MS analysis of serum samples from uremic patients and normal subjects. 
(triangles, the control group; diamonds, the uremic group)  
 
 
 
 
 
 
 
 
Table 4: List of the significant metabolites identified from OPLS-DA modeling of the metabolic 
profiles of uremic patients and health control objects  
RT (min) m/z a  Metabolites P (t-test)  Fold change 
10.448 144, 101, 116, 72, 55 Valine 0.022 −1.871 
11.784 158, 102, 43, 58, 72 Leucine 0.039 −1.648 
12.091 158, 102, 129, 69, 74 Isoleucine 0.0161 −2.890 
19.052 88, 101, 158, 256, 211 Tetradecanoic acid 0.002 +8.690 
27.146 55, 67, 81, 211, 280 9,12-Octadecadienoic acid 0.033 +7.516 
aTypical ion fragmentations for the compound.  
 
Fold change is based on a two-tailed Student's t-test, and it expresses the difference in 
concentrations between the uremic patient group and the control subject group; “+”and “-” 
indicate increased and decreased concentrations of metabolites, respectively, in the uremic 
patients versus the control subjects.  
 
An abnormal accumulation of fatty acids such as myristic acid and linoleic acid was observed in 
serum samples from uremic patients in this study. The oxidation and metabolism of linoleic acid 
yields many biologically active compounds such as linolic acid monoepoxides and the 
corresponding diol metabolites through cytochrome P450. The accumulation of these metabolites 
in the kidney could induce mitochondrial dysfunction and cause cell death, which are usually 
responsible for acute kidney impairment [26, 27]. Myristic acid exhibited a protective effect on 
renal necrosis in rats fed a methyl-deficient diet; however, it should be investigated whether the 
level of myristic acid in the uremic patient serum increased as a metabolic compensation for 
uremia-related pathological variations. Numerous studies have reported that carnitine plays an 
indispensable role in the oxidation and metabolism of fatty acids, thus, the lineloic acid and 
myristic acid disorders observed in uremic patient sera probably reflect the depletion of carnitine 
[28], which has significant consequences for patients with myocardial diseases and kidney 
failure.  
 
In addition to the accumulated metabolites identified in the uremic patient sera, significantly 
decreased concentrations of certain branched-chain amino acids (BCAAs) including valine, 
leucine and isoleucine were observed compared to those of normal subjects. The decreased 
concentrations of these three amino acids in uremic patients presumably resulted from their 
increased oxidation, which often serves as an alternative energy source.  
 
Despite the fact that these preliminary results, such as the accumulation of fatty acids and the 
depletion of amino acids, were obtained from a relatively small-scale clinical study, the findings 
are rational and in good agreement with conventional studies that centered mainly on individual 
or certain metabolites [29–31]. Therefore, the proposed GC-MS-based metabolic profiling 
technology is able to characterize the metabolic disturbances associated with human uremia, and 
so it potentially provides a holistic therapeutic strategy for uremic patients. Further studies will 
be initiated in order to identify more of the various metabolites responsible for uremia in a large-
scale clinical study using GC-MS in combination with other analytical techniques such as NMR 
and UPLC-QTOF-MS, and to evaluate the therapeutic efficacies of different dialysis 
prescriptions.  
 
CONCLUSION 
The major characteristics of the analytical method reported here is a simple and efficient ECF 
derivatization procedure coupled with the conventional use of high-throughput GC-MS. The 
proposed method exhibited satisfactory linearity and 48-h stability, and acceptable analytical 
method and equipment repeatability, thus facilitating the global analysis of a broad array of 
metabolites present in complex serum samples. This method was successfully applied in a 
serum-based metabonomic study on human uremia, and preliminary results allowed the 
identification of several significant differences in metabolic function between uremic patients 
and normal subjects. These results, combined with the simplicity, reliability, and repeatability of 
the protocol, indicate that this optimized method can be widely applied to metabonomic studies 
of serum samples.  
 
ABBREVIATIONS 
GC-MS   Gas chromatography–mass spectrometry 
LOD    Limit of detection 
RSD    Relative standard deviation 
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